Barely Significant
← all excerpts

The Treatment of Lung Involvement in Systemic Sclerosis.

Pharmaceuticals (Basel) · 2021 · PMC7918752 · PMID 33668530

Europe PMCDOI
1
hedged sentence
0.1100
closest p · 2.2× alpha
0.1100
boldest claim

The sentences

showed a trendp = 0,11not close (p > 0.1)
Finally, a recent phase II multicentre double-blind placebo-controlled trial of abatacept in early dcSSc showed a trend for a significant lower decline of FVC% predicted (mean difference 2.79, 95% CI −0,69–6,27, p = 0,11 favouring Abatacept), although the change in skin fibrosis as a primary endpoint was, again, not met [ 57 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.